SGLT2 inhibitor reduces the risk of hyperkalemia in patients with heart failure.

Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled – European Heart Journal

Editorial: Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure

Related: Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial – European Heart Journal

Commentary on Twitter

More evidence that SGLT2i ⬇️ hyperK, this time in heart failure

Empagliflozin reduces:
– K>6.0: HR 0.62 95% CI 0.48–0.81
– Investigator reported hyperK or K binders, HR 0.82 95% CI 0.71-0.95
– Effect modified by GFR – larger in CKD
– Regardless of MRAshttps://t.co/t4T7II1G8p pic.twitter.com/RP1EUKXHyV

— Brendon Neuen (@brendonneuen) June 12, 2022

Under a https://creativecommons.org/licenses/by-nc/4.0/ license